What if we could
cure fatal rare
Rare Monogenic Disease
Many rare diseases are caused by a single mutation in a gene, which leads to a build up of a misfolded, non-functional protein. These proteins go on to do serious damage to the cell and therefore cause often significant disease. And very often they inhibit the ability of the cell to undergo autophagy which itself leads to more damage.
So if we boost autophagy we can remove the misfolded, cytotoxic protein, restore the cell’s ability to undergo autophagy, and in some cases we find that we can also restore the function of the mutated protein. This means restoring autophagy is not just helping an aspect of the disease but is truly curative.
In Samsara we are studying specific rare genetic peripheral nervous system and liver diseases where we believe autophagy can be completely curative.
This could be life-changing for many patients suffering with severe diseases which are currently poorly treated.
Samsara Therapeutics adds eminent neurologist Professor Dame Pamela Shaw to its scientific advisory board to help accelerate ALS/MND treatment development
Samsara Therapeutics, the autophagy biotech company, has appointed eminent neurologist and world-leading researcher in Amyotrophic Lateral Sclerosis (ALS)/Motor Neuron Disease (MND) Professor Dame Pamela Shaw to its scientific advisory board.
Samsara Therapeutics announced today that it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to further its research into a promising Parkinson’s disease drug.
Samsara Therapeutics unveils promising autophagy drug candidate, offering new hope for people with Parkinson’s and motor neurone disease
Samsara Therapeutics is first in the race to find a viable, potent autophagy inducing drug, with the potential to give us longer and healthier lives.
We caught up with Senior Scientists Gabriela Vilema Enríquez and Matthew Williamson on their work within the neuroscience team at Samsara.